MedPath

To Evaluate the Efficacy and Safety of MaxioCel Versus Aquacel Extra for the Management of Chronic Wounds

Not Applicable
Recruiting
Conditions
Wound
Registration Number
NCT05312762
Lead Sponsor
Axio Biosolutions Pvt. Ltd.
Brief Summary

The objective of this study is to evaluate the efficacy and safety of MaxioCel vs Aquacel Extra in the management of exuding ulcers/wounds over a period of 4 weeks

Detailed Description

The current study intends to compare the efficacy of the chitosan wound dressing (MaxioCel) with another marketed dressing (Aquacel Extra). MaxioCel is made up of chitosan and Aquacel Extra with carboxymethyl cellulose. Both are polymeric dressings.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
118
Inclusion Criteria
  • Male or female 18 years old or above (till 80 years)
  • Patients who are willing to sign the written informed consent
  • Clinically diagnosed with an unhealed or non-healing diabetic foot ulcer / venous ulcer / arterial ulcer / other ulcers / wounds, etc.
  • Wound duration between 1 to 24 months
  • A target wound area between 1 cm2 and 50 cm2
  • Exuding wounds / ulcers
Exclusion Criteria
  • Known allergy/hypersensitivity to the dressing
  • Pregnant women
  • Underlying or diagnosed with serious diseases or deemed unsuitable for this clinical study by the study's clinician
  • Dry wounds
  • Being treated with a high dose of steroids or immunosuppressant therapy or systemic antibiotics
  • Presenting a progressive neoplastic lesion treated with radiotherapy or chemotherapy
  • Patients who had Deep Vein Thrombosis in the previous 3 months
  • Ulcers with clinical signs of infection or erysipelas of the lower limb or biofilm
  • Subjects included in clinical study at present or during the past 30 days
  • Clinical suspicion of osteomyelitis

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Wound Area MeasurementWeek 1, Week 2, Week 3, Week 4

Wound area (cm2) to be recorded at baseline and weekly visits to assess % change in wound area.

Secondary Outcome Measures
NameTimeMethod
Changes in Epithilizing / Granulating TissuesWeek 1, Week 2, Week 3, Week 4

measured by % change in Epithelizing and granulating tissues

Scar ManagementWeek 4

Vancouver Scar Scale will be used at the final visit to evaluate the scar formation at wound site. Minimum score - 0; Maximum score - 13

Pain ManagementWeek 1, Week 2, Week 3, Week 4

Changes in pain using Numeric Rating Scale (0-10). 0 means no pain, 10 means severe pain/worst possible pain

Clinician opinion related to dressingWeek 4

Dressing usability / use of dressing will be evaluated via questionnaire. The options for rating will be Excellent, Good, Fair, Poor. For few questions, options will be Yes or No

Exudate ManagementWeek 1, Week 2, Week 3, Week 4

Change in Exudate levels will be evaluated. Exudate levels will be evaluated as per below categories:

None, Scant, Small, Moderate, Large

Bates Janesen Wound Assessment ScoreWeek 1, Week 2, Week 3, Week 4

The status of wound as per 13 items mentioned in the Bates-Jensen Wound Assessment Tool will be evaluated. Higher the total score, the more severe the wound status.Minimum score - 13 ; Maximum score - 65

Patient opinion related to dressingWeek 4

Patients comfort levels with use of dressing will be evaluated via questionnaire. The options for rating will be Excellent, Good, Fair, Poor. For few questions, options will be Yes or No

Trial Locations

Locations (5)

Saveetha Medical College Hospital

🇮🇳

Chennai, Tamil Nadu, India

Hycare Super Speciality Hospital

🇮🇳

Chennai, Tamilnadu, India

Vijaya hospitals

🇮🇳

Chennai, India

Kamineni Hospitals Pvt Ltd

🇮🇳

Hyderabad, India

Yalamanchi hospital and research center vijayawada

🇮🇳

Vijayawada, India

Saveetha Medical College Hospital
🇮🇳Chennai, Tamil Nadu, India
Gowtham
Contact

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.